A Comprehensive Guide to the Treatment of Atrial Fibrillation with Dabigatran Etexilate
Dabigatran etexilate (Pradaxa) was approved by the FDA in 2010 as the first oral direct thrombin inhibitor for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. This article will provide a comprehensive overview of dabigatran based on clinical trial data and practical considerations for its use.
Key Points
Pharmacokinetic profile and...
0 Comments
0 Shares
5630 Views
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek